Drug Profile
Research programme: heat shock protein 90 inhibitors - Serenex
Alternative Names: PF-04928473; PF-4928473; SNX 0723; SNX 2112; SNX-3133; SNX-5542Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Serenex
- Developer Pfizer; Serenex
- Class Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Cancer; Head and neck cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA (PO)